PERU Clinical Trial Unit

Asociacion Civil Impacta Salud Y Educacn, Lima

Investigators

Linked publications, trials & patents

Abstract

PERU CTU. April 2024 PROJECT SUMMARY/ABSTRACT The proposed renewal of the PERU Clinical Trials Unit (CTU) is built on the strengths of the long-standing consortium between the Asociacion Civil Impacta Salud y Educacion (IMPACTA) and the Asociacion Civil Selva Amazonica (ACSA), two nonprofit research institutions in Peru. They have received over $110 million of investment from the U.S. NIH during the past 19 years, to establish a comprehensive infrastructure able to support the implementation of multiple and complex studies from diverse U.S. NIH HIV/AIDS clinical research networks and to rapidly respond to evolving research opportunities. Two new institutions are added in this renewal proposal, the Centro de Investigaciones Tecnologicas, Biomedicas y Medioambientales (CITBM) and the Asociacion Civil Via Libre. The proposed PERU CTU will be led by Dr. Jorge Sanchez (based at CITBM) and Dr. Alberto La Rosa (based at IMPACTA), and supported by a cadre of experienced researchers and promising junior investigators. The PERU CTU consolidated a three- dimensional matrix organization to support the increasing number and complexity of studies from multiple HIV/AIDS clinical trial networks, and has effectively utilized its intellectual and structural resources to create and update innovative tools for more efficient operations. The PERU CTU proposes to continue efficient and ethical implementation of the clinical research agenda of the HIV Prevention Trials Network (HPTN), HIV Vaccine Trials Network (HVTN), and AIDS Clinical Trials Group (ACTG), at four Clinical Research Sites (CRSs) in Lima (Barranco, CITBM, San Miguel and Via Libre), and one CRS in Iquitos (ACSA)